New drug combo aims to wipe out hepatitis c in Hard-to-Treat patients
NCT ID NCT07316842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to see how well this drug combination works in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ravidasvir and sofosbuvir
- What this could lead to
- If successful, this could confirm that the combination of ravidasvir and sofosbuvir effectively clears the hepatitis C virus in people with genotype 3 and mild liver damage.
- What could go wrong
- This is a small observational study with only 30 participants, so results may not apply to everyone. It is not a randomized trial, and the long-term durability of the response beyond 12 weeks is not assessed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C GENOTYPE 3 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.